Hiv-1 Genotyping Assay Using Ngs Technology
QIC is the FDA product code for Hiv-1 Genotyping Assay Using Ngs Technology, a class II device type, regulated under 21 CFR 866.3955. FDA's definition for this code reads: "The human immunodeficiency virus (HIV) drug resistance genotyping assay using next generation sequencing (NGS) technology is a prescription in vitro diagnostic device intended for use in detecting HIV genomic mutations that confer resistance to specific anti-retroviral drugs. The device is intended to be used as an...". As of , FDA records hold no 510(k) clearances under this code and no recalls.
Classification record
- Product code
- QIC
- Device name
- Hiv-1 Genotyping Assay Using Ngs Technology
- FDA definition
- The human immunodeficiency virus (HIV) drug resistance genotyping assay using next generation sequencing (NGS) technology is a prescription in vitro diagnostic device intended for use in detecting HIV genomic mutations that confer resistance to specific anti-retroviral drugs. The device is intended to be used as an aid in monitoring and treating HIV infection.
- Regulation
- 21 CFR 866.3955
- Device class
- Class II
- Review panel
- Medical Genetics
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 0
- Ingested recalls
- 0
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
